According to @CNBC, HHS Secretary Robert F. Kennedy Jr.’s hand-picked vaccine committee voted on Friday to end the long-standing universal recommendation that all babies receive a hepatitis B shot at birth, issuing weaker guidance for certain infants, source: CNBC. According to @CNBC, this reflects a shift from prior nationwide guidance applied to all newborns at birth, source: CNBC. According to @CNBC, the report was posted on Dec 5, 2025, defining the timing of this policy headline for market calendars, source: CNBC.

According to Mark Cuban on Twitter, Cost Plus Drugs has announced partnerships with several transparent, pass-through pharmacy benefit managers (PBMs), encouraging decision-makers to consult these PBMs before finalizing any corporate pharmacy benefits (Source: @mcuban, May 6, 2025). For investors and trading professionals in the healthcare and pharmaceutical sectors, this move signals a shift towards greater price transparency and potentially lower drug costs, which could impact the stock performance of traditional PBMs and benefit transparency-focused companies.